Author information:
(1)Departamento de Hematologia, Hospital Universitari i Politècnic La Fe, 
València, Spain.
(2)CIBERONC, Instituto Carlos III, Madrid, Spain.
(3)F. Hoffmann-La Roche Ltd, Basel, Switzerland.
(4)Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain.
(5)Department of Leukemia, Division of Cancer Medicine, The University of Texas 
MD Anderson Cancer Center, Houston, TX, USA.
(6)Department of Hematology and Sciences Oncology, Istituto Scientifico 
Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
(7)Department of Experimental, Diagnostic and Specialty Medicine Institute of 
Hematology & Medical Oncology L & A Seràgnoli, Bologna, Italy.
(8)Hoffmann-La Roche Ltd, Mississauga, ON, Canada.
(9)Serviced'Hématologie, Institut Universitaire du Cancer Toulouse - 
Oncopole,Toulouse, France.
(10)Department of Internal Medicine, Universitätsklinikum Carl Gustav Carus, 
Dresden, Germany.
(11)Hematology Department, Aix-Marseille University, Institut Paoli-Calmettes, 
Marseille, France.
(12)Department of Haematology, The Alfred Hospital & Monash University, 
Melbourne, VIC, Australia.
(13)Division of Hematology/Medical Oncology, Department of Internal Medicine, 
Seoul National University Hospital, Seoul, South Korea.
(14)Service d'Hématologie Séniors Hôpital Saint-Louis, Assistance Publique - 
Hôpitaux de Paris, Université de Paris, Paris, France.